



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Zanamivir-¹³C,¹⁵N₂
Item No. 30733

CAS Registry No.: 1276528-62-1
Formal Name: 5-(acetylamino)-4-[(amino-¹⁵N-imino-¹⁵N-methyl-¹³C)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-ido-non-2-enonic acid
MF: C₁₁[¹³C]H₂₀N₂[¹⁵N]₂O₇
FW: 335.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Zanamivir-¹³C,¹⁵N₂ is supplied as a solid. A stock solution may be made by dissolving the zanamivir-¹³C,¹⁵N₂ in water. Zanamivir-¹³C,¹⁵N₂ is slightly soluble in water. We do not recommend storing the aqueous solution for more than one day.

Description

Zanamivir-¹³C,¹⁵N₂ is intended for use as an internal standard for the quantification of zanamivir (Item No. 15123) by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.¹ It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC₅₀ values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC₅₀ values ranging from 0.6 to 7.9 nM *in vitro*. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.

Reference

1. Elliott, M. Zanamivir: From drug design to the clinic. *Philos. Trans. R. Soc. Lond. B Biol Sci.* **356**(1416), 1885-1893 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/15/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM